Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Tax Provisions (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Tax Provisions data on record, last reported at -$3.2 million in Q3 2025.

  • For Q3 2025, Tax Provisions fell 4574.65% year-over-year to -$3.2 million; the TTM value through Sep 2025 reached $1.0 million, up 164.06%, while the annual FY2024 figure was $2.6 million, 660.36% up from the prior year.
  • Tax Provisions reached -$3.2 million in Q3 2025 per GLUE's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $2.2 million in Q4 2024 and bottomed at -$3.2 million in Q3 2025.
  • Average Tax Provisions over 3 years is $175800.0, with a median of $180000.0 recorded in 2023.
  • Peak YoY movement for Tax Provisions: soared 9963.64% in 2024, then crashed 4574.65% in 2025.
  • A 3-year view of Tax Provisions shows it stood at -$22000.0 in 2023, then skyrocketed by 9963.64% to $2.2 million in 2024, then tumbled by 246.41% to -$3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$3.2 million in Q3 2025, $1.2 million in Q2 2025, and $800000.0 in Q1 2025.